Fox Run Management L.l.c. adds Incyte Corporation (INCY) to its portfolio

Incyte Corporation (INCY) : Fox Run Management L.l.c. added new position in Incyte Corporation during the most recent quarter end. The investment management firm now holds 10,600 shares of Incyte Corporation which is valued at $920,928 , the company said in a statement filed on Jul 18, 2016 with the SEC.Incyte Corporation makes up approximately 0.43% of Fox Run Management L.l.c.’s portfolio.

Other Hedge Funds, Including , Foundry Partners reduced its stake in INCY by selling 11,045 shares or 56.02% in the most recent quarter. The Hedge Fund company now holds 8,670 shares of INCY which is valued at $715,795. Incyte Corporation makes up approx 0.07% of Foundry Partners’s portfolio.Fisher Asset Management reduced its stake in INCY by selling 21 shares or 0.14% in the most recent quarter. The Hedge Fund company now holds 14,818 shares of INCY which is valued at $1,223,374.Benjamin F. Edwards Company reduced its stake in INCY by selling 200 shares or 40.0% in the most recent quarter. The Hedge Fund company now holds 300 shares of INCY which is valued at $24,768.Bnp Paribas Arbitrage Sa reduced its stake in INCY by selling 22,770 shares or 54.93% in the most recent quarter. The Hedge Fund company now holds 18,683 shares of INCY which is valued at $1,601,133. Incyte Corporation makes up approx 0.01% of Bnp Paribas Arbitrage Sa’s portfolio.

Incyte Corporation opened for trading at $82.91 and hit $87.19 on the upside on Wednesday, eventually ending the session at $86.88, with a gain of 4.90% or 4.06 points. The heightened volatility saw the trading volume jump to 14,41,014 shares. Company has a market cap of $16,300 M.

On the company’s financial health, Incyte Corporation reported $0.12 EPS for the quarter, based on the information available during the earnings call on May 9, 2016. Analyst had a consensus estimate of $0.12. The company had revenue of $263.50 million for the quarter, compared to analysts expectations of $264.41 million. The company’s revenue was up 65.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.11 EPS.

Many Wall Street Analysts have commented on Incyte Corporation. RBC Capital Mkts Initiated Incyte Corporation on Jul 13, 2016 to “Outperform”, Price Target of the shares are set at $105.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company’s compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received development and commercialization rights f

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Incyte Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Incyte Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.